These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10487453)

  • 1. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
    Zerehsaz F; Salmanpour R; Handjani F; Ardehali S; Panjehshahin MR; Tabei SZ; Tabatabaee HR
    Int J Dermatol; 1999 Aug; 38(8):610-2. PubMed ID: 10487453
    [No Abstract]   [Full Text] [Related]  

  • 2. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
    Mujtaba G; Khalid M
    Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
    [No Abstract]   [Full Text] [Related]  

  • 3. A double-blind randomized clinical trial of a topical herbal extract (Z-he) vs. systemic meglumine antimonate.
    Momeni AZ; Aminjavaheri M
    Int J Dermatol; 2000 Nov; 39(11):880. PubMed ID: 11123462
    [No Abstract]   [Full Text] [Related]  

  • 4. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
    Aste N; Pau M; Ferreli C; Biggio P
    Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G; Tavakoli-kia R
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
    Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
    López L; Robayo M; Vargas M; Vélez ID
    Trials; 2012 May; 13():58. PubMed ID: 22594858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of efficacy of liposomal glucantime in the treatment of cutaneous leishmaniasis.
    Ghoyonlo VM; Jafari MR; Yazdanpanah MJ; Esmaili H; Noori S; Kiafar B
    Indian J Dermatol Venereol Leprol; 2016; 82(3):347-9. PubMed ID: 27088953
    [No Abstract]   [Full Text] [Related]  

  • 10. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
    Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
    Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
    Shamsi Meymandi S; Javadi A; Dabiri S; Shamsi Meymandi M; Nadji M
    Arch Iran Med; 2011 Jul; 14(4):238-43. PubMed ID: 21726098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antimonial treatments of leishmaniasis].
    Oliveira Neto MP
    Rev Soc Bras Med Trop; 2005; 38(5):446. PubMed ID: 16172767
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
    Shanehsaz SM; Ishkhanian S
    Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful therapeutic response of resistant cases of mucocutaneous leishmaniasis to a very low dose of antimony.
    de Oliveira-Neto MP; Mattos Mda S
    Rev Soc Bras Med Trop; 2006; 39(4):376-8. PubMed ID: 17119754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
    Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
    Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
    Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
    J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
    Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
    Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis.
    Iraji F; Vali A; Asilian A; Shahtalebi MA; Momeni AZ
    Dermatology; 2004; 209(1):46-9. PubMed ID: 15237267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.